



Half-yearly Financial Report 2015

Press and analyst presentation

14 July 2015

ADC technology

- Research results from collaboration with the MD Anderson Cancer Center published in NATURE, first personalised medicine approach for ADCs
- PSMA-ATAC project granted € 0.9 m for the development of a prostate cancer treatment from the Federal Ministry of Education and Research (BMBF)
- European Union granted the ETN MAGICBULLET consortium (9 research groups) a total of € 3.75 m for the development of new peptide-based concepts for anti-tumour therapies

Clinical pipeline


- Agreement with Link Health on the immediate transfer of a number of MESUPRON[®] patents, which are needed to apply for grants under a national subsidy programme, a partial of the milestone payment €500 k became due
- Know-how support for MESUPRON[®] partners RedHill and Link Health
- Partnering discussion for REDECTANE[®] and RENCAREX[®] ongoing

Rights issue using authorised capital successfully completed in Q2

Rights Issue

- Gross proceeds of € 4.16 million to finance the further development of the ADC technology
- Volume: 1,486,732 new shares
- Subscription price: € 2.80
- Ratio: 21 old : 4 new
- Subscription period: 20 March - 7 April 2015
- New share capital: 9,305,608
- Participation of the main shareholder dievini, corporate bodies and dedicated life science investors
- New shares with different ISIN DE000A14KND2 / WKN A14KND until the end of July

Shareholder structure




* Including companies controlled by him:
dievini Hopp BioTech, DH-Holding, Curacyte

Income

€ m; rounded


■ Sales revenue
■ Other income



Operating expenses


€ m; rounded

■ Cost of sales
■ Research and development costs
■ Administrative costs
■ Other expenses




Net loss for the period

€ m; rounded




- Operating expenses were significantly lower than previous year




Assets

€ m; rounded




Equity and liabilities

€ m; rounded




Cash flow H1 2015

€ m; rounded



- Total assets higher than 2014 due to capital increase
- Equity increased to € 14.1 m, equity ratio was 82.4%
- Cash balance as at 30.05.2015: € 4.1 m
- Average cash usage per month € 0.4 m (2014: € 1.0 m) in line with guidance

Share performance and volumes 2015



Share performance H1 2015 (FY)

High: € 5.55 (6 May 2015)
 Low: € 1.73 (6 January 2015)
 Daily trading volume: 19,869

Analyst coverage

EDISON: target € 6.13 per share = € 57 m
 Equinet: target € 5.52 per share = € 51 m
 Current market cap: ~€ 31 m

AGM

- Election of the new Supervisory Board
- Authorised Capital 2012/I and contingent capital: Lifting of self-restriction to 4.46 million shares authorised capital 2012/I and 2.14 million shares contingent capital

ADC business

- Start of GMP Transfer Amanitin
- Start development of first proprietary ATAC candidate
- Preclinical validation of new biomarker
- Mature the ADC technology platform

Clinical assets

- REDECTANE® / RENCAREX®: New partners for development and commercialisation, out-licensing
- MESUPRON®: Support development activities of RedHill and Link Health

in € m	Actual 2014	Plan
Sales revenue and other income	5.0	4.0 – 6.0
Operating expenses	10.6	7.0 – 10.0
Operating result (EBIT)	(5.6)	(2.0 – 5.0)
Total funding requirement	6.7	3.0 – 5.0
Funds required per month	0.6	0.3 – 0.4

Financial Calendar 2015

30 July: AGM

15 Oct: 9-month Financial Report

- Sales mainly driven by ADC technology business and services at Heidelberg Pharma
- Other income mainly comprise government grants and income from sub-letting premises
- WILEX's cash reach is secured into Q2 2016

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of WILEX AG. This material may not be distributed within countries where it may violate applicable law.

WILEX AG

Grillparzerstr. 18
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-0
Fax: +49 (0)89-41 31 38-99
Website: www.wilex.com

IR/PR support

MC Services AG
Katja Arnold (CIRO)
Email: [katja.arnold\[at\]mc-services.eu](mailto:katja.arnold[at]mc-services.eu)
Tel.: +49 (0)89-210 288 40

Ticker data

ISIN: DE000A11QVV0
Symbol: WL6
Reuters: WL6G.DE
Bloomberg: WL6.GR